New financing for Biognosys

End of December 2013 Biognosys has secured 1 million financing. This financing will ensure future growth of the company by expanding its commercial operations and product development.

In addition, Biognosys strengthened the existing management team by appointing Russell Golson as Director of Sales and Lukas Reiter as Head of Research & Development. Russel Golson has held management positions in life science tools companies including MWG Biotech, Febit GmbH and latterly BioSilta where he led the development and commercialization department. Lukas Reiter graduated at the ETH Zurich in biochemistry/molecular biology. For his PhD he joined the groups of Micheal Hengartner and Ruedi Aebersold and received his degree in 2009 from the University of Zurich. After completing his PhD he was a PostDoc for one year and in parallel started at Biognosys, working on professionalizing the software development and applying it to novel acquisition techniques such as SWATH. 

Biognosys was founded in 2008 and is a privately held company in Zurich. Biognosys’ breakthrough mass spectrometric technology allows the simultaneous measurement of thousands of proteins in a single sample. The information is then stored in a digital map, which acts as a tool to monitor health, detect the onset of diseases, and discover biomarkers.